Skip to content

Clinical Trial Evaluating the Efficiency of Holmium Laser Settings on Urinary Stones

Clinical Trial Evaluating the Efficiency of Holmium Laser Settings on Urinary Stones

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03526458
Enrollment
40
Registered
2018-05-16
Start date
2019-07-30
Completion date
2021-03-24
Last updated
2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stone;Renal, Stone Ureter, Surgery

Keywords

Holmium Laser, Laser setting, Stone fragmentation

Brief summary

The primary objective of this study is to compare the time to acceptable stone fragmentation during clinical use of the holmium laser when using energy settings 0.2J vs 0.8J. The hypothesis is that holmium laser energy settings 0.8J will require less time than lower energy settings 0.2J for fragmenting urinary stones. The clinical practice is to treat urinary stones until the stone is reduced to fragments ≤ 2 mm in size. This is determined by using the laser fiber which is 273 microns to visually estimate the size of the resultant fragments as described by Patel et al, J Endo 2014. Investigators will standardize the effect of stone size by creating a ratio of stone size to treatment time. In this study, the frequency is set at 15Hz. Thus, the study contains two arms: 0.2J&15Hz, and 0.8J&15Hz. Patients will be randomized into the two groups by the ratio of 1:1.

Detailed description

The only interventions imposed on subjects as a result of this study are (1) pre-procedural randomization to laser lithotripsy with either 0.2J or 0.8J energy setting, and (2) the use of patient information in describing results. All the other activities are part of the routine clinical practice in the department. Participation in the study will not alter the patients' preoperative, or postoperative care. During surgery, patients' stones will be treated in accordance with the routine clinical practice of fragmenting stones into small pieces (\<2 mm). All patients enrolled will undergo routine post-operative follow up including clinic appointments and imaging evaluation. Any complications will be recorded, reported, and treated appropriately. A fixed frequency will be used (15Hz). Thus, the study contains two arms: 0.2J&15Hz, and 0.8J&15Hz. Patients will be randomized into the two groups by the ratio of 1:1. A total of 1 clinic visit (i.e., the stone surgery, approximately 5-6 hours, depending on the duration of the surgery) is needed for this study. The study procedures are: 1. A study team member who is affiliated with the patient's clinical care (e.g., the surgeon) will initially approach the patients who are scheduled laser lithotripsy treatment of urinary stones. (i.e. informed that there's a research study they may be eligible for, and asked if they want to learn more about it). 2. If the patient is interested in the study, a member of the research team will approach him/her for enrollment. 3. Once the consent form is obtained, patients' medical background will be reviewed for inclusion/exclusion criteria. Patients who meet the inclusion criteria will be included in the study; patients who do not meet the inclusion criteria will be excluded. 4. Patients will be randomized to either 0.2J&15Hz or 0.8J&15Hz (randomization ratio 1:1) group. 5. Patients will undergo stone surgeries with the laser setting that they are randomized to. The patient's stone(s) will be treated in accordance with the routine clinical practice of fragmenting stone into small pieces (≤ 2mm). The faculty surgeon (i.e., Dr. Nakada) will perform all surgeries. 6. Fragmentation time as well as other information (total surgery time, complications, stone information, and number of stones treated) is collected. 7. After surgery, the patients will then continue on normal postoperative pathway. Postoperative complications will be collected.

Interventions

DEVICEHolmium:YAG laser

Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients at least 18 years of age * Patients with urinary stones who require endoscopic treatment

Exclusion criteria

* Patients \< 18 years of age * Pregnant patients * Pre-menopausal females who have not been on approved birth control for at least 1 month pre-operatively * Patients with stones known to be refractory to treatment with the holmium laser

Design outcomes

Primary

MeasureTime frameDescription
Fragmentation Timeup to 6 hoursThe time to fragment a stone into small pieces (≤2 mm, which is our current institutional practice)

Secondary

MeasureTime frameDescription
Number of Participants With Urinary Stone Fragment Size of 1, 2 or 3 mmup to 6 hoursSize of fragments created will be assessed using the laser fiber size as a comparison.
Total Operative Timeup to 6 hours
Density of Urinary Stonesup to 6 hours
Number of Participants With Either Ureteral or Renal Location of Urinary Stoneup to 6 hoursUrinary stone location will be classified as renal or ureter.
Number of Participants Treated for Either Single or Multiple Urinary Stonesup to 6 hours
Pre-Operative Stone SizeRetrospective review of health chart at BaselinePre-operative stone size (on pre-operative CT) will be reported in millimeters.

Countries

United States

Participant flow

Participants by arm

ArmCount
Holmium:YAG Laser: 0.2J&15Hz
Patients are assigned to treat stones with 0.2J&15Hz of the holmium laser. Holmium:YAG laser: Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
12
Holmium:YAG Laser: 0.8J&15Hz
Patients are assigned to treat stones with 0.8J&15Hz of the holmium laser. Holmium:YAG laser: Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
15
Total27

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLack of equipment11
Overall StudyPhysician Decision21
Overall StudyStone passed, surgery cancelled21
Overall StudySurgeries rescheduled or cancelled due to COVID22
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicHolmium:YAG Laser: 0.2J&15HzTotalHolmium:YAG Laser: 0.8J&15Hz
Age, Continuous51 years
STANDARD_DEVIATION 15.4
53.6 years
STANDARD_DEVIATION 14.1
55.6 years
STANDARD_DEVIATION 13.1
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
12 Participants27 Participants15 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
12 Participants27 Participants15 Participants
Region of Enrollment
United States
12 participants27 participants15 participants
Sex: Female, Male
Female
5 Participants13 Participants8 Participants
Sex: Female, Male
Male
7 Participants14 Participants7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 120 / 15
other
Total, other adverse events
0 / 120 / 15
serious
Total, serious adverse events
0 / 120 / 15

Outcome results

Primary

Fragmentation Time

The time to fragment a stone into small pieces (≤2 mm, which is our current institutional practice)

Time frame: up to 6 hours

ArmMeasureValue (MEAN)Dispersion
Holmium:YAG Laser: 0.2J&15HzFragmentation Time24.5 MinutesStandard Deviation 19.2
Holmium:YAG Laser: 0.8J&15HzFragmentation Time7.9 MinutesStandard Deviation 3.2
p-value: 0.01295% CI: [4.4, 28.9]t-test, 2 sided
Secondary

Density of Urinary Stones

Time frame: up to 6 hours

ArmMeasureValue (MEAN)Dispersion
Holmium:YAG Laser: 0.2J&15HzDensity of Urinary Stones935.2 Hounsfield unitsStandard Deviation 367.9
Holmium:YAG Laser: 0.8J&15HzDensity of Urinary Stones924.7 Hounsfield unitsStandard Deviation 374.5
p-value: 0.94395% CI: [-286, 306.8]t-test, 2 sided
Secondary

Number of Participants Treated for Either Single or Multiple Urinary Stones

Time frame: up to 6 hours

ArmMeasureGroupValue (NUMBER)
Holmium:YAG Laser: 0.2J&15HzNumber of Participants Treated for Either Single or Multiple Urinary StonesSingle8 Participants
Holmium:YAG Laser: 0.2J&15HzNumber of Participants Treated for Either Single or Multiple Urinary StonesMultiple4 Participants
Holmium:YAG Laser: 0.8J&15HzNumber of Participants Treated for Either Single or Multiple Urinary StonesSingle14 Participants
Holmium:YAG Laser: 0.8J&15HzNumber of Participants Treated for Either Single or Multiple Urinary StonesMultiple1 Participants
p-value: 0.076Chi-squared
Secondary

Number of Participants With Either Ureteral or Renal Location of Urinary Stone

Urinary stone location will be classified as renal or ureter.

Time frame: up to 6 hours

ArmMeasureGroupValue (NUMBER)
Holmium:YAG Laser: 0.2J&15HzNumber of Participants With Either Ureteral or Renal Location of Urinary StoneUreteral8 Participants
Holmium:YAG Laser: 0.2J&15HzNumber of Participants With Either Ureteral or Renal Location of Urinary StoneRenal4 Participants
Holmium:YAG Laser: 0.8J&15HzNumber of Participants With Either Ureteral or Renal Location of Urinary StoneUreteral7 Participants
Holmium:YAG Laser: 0.8J&15HzNumber of Participants With Either Ureteral or Renal Location of Urinary StoneRenal8 Participants
p-value: 0.299Chi-squared
Secondary

Number of Participants With Urinary Stone Fragment Size of 1, 2 or 3 mm

Size of fragments created will be assessed using the laser fiber size as a comparison.

Time frame: up to 6 hours

ArmMeasureGroupValue (NUMBER)
Holmium:YAG Laser: 0.2J&15HzNumber of Participants With Urinary Stone Fragment Size of 1, 2 or 3 mm1mm1 Participants
Holmium:YAG Laser: 0.2J&15HzNumber of Participants With Urinary Stone Fragment Size of 1, 2 or 3 mm2mm10 Participants
Holmium:YAG Laser: 0.2J&15HzNumber of Participants With Urinary Stone Fragment Size of 1, 2 or 3 mm3mm1 Participants
Holmium:YAG Laser: 0.8J&15HzNumber of Participants With Urinary Stone Fragment Size of 1, 2 or 3 mm1mm5 Participants
Holmium:YAG Laser: 0.8J&15HzNumber of Participants With Urinary Stone Fragment Size of 1, 2 or 3 mm2mm10 Participants
Holmium:YAG Laser: 0.8J&15HzNumber of Participants With Urinary Stone Fragment Size of 1, 2 or 3 mm3mm0 Participants
p-value: 0.185Chi-squared
Secondary

Pre-Operative Stone Size

Pre-operative stone size (on pre-operative CT) will be reported in millimeters.

Time frame: Retrospective review of health chart at Baseline

ArmMeasureValue (MEAN)Dispersion
Holmium:YAG Laser: 0.2J&15HzPre-Operative Stone Size11.2 mmStandard Deviation 5.2
Holmium:YAG Laser: 0.8J&15HzPre-Operative Stone Size9.2 mmStandard Deviation 8.2
p-value: 0.65495% CI: [-4.4, 6.9]t-test, 2 sided
Secondary

Total Operative Time

Time frame: up to 6 hours

ArmMeasureValue (MEAN)Dispersion
Holmium:YAG Laser: 0.2J&15HzTotal Operative Time75.7 MinutesStandard Deviation 20.6
Holmium:YAG Laser: 0.8J&15HzTotal Operative Time64.3 MinutesStandard Deviation 17.2
p-value: 0.13295% CI: [-3.6, 26.3]t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026